Adviser to Xceleron Inc. on its sale to Pharmaron

Transaction Summary

Strata Partners is delighted to announce the sale of Xceleron Inc., the Maryland, US-based globally leading Accelerator Mass Spectrometry (AMS) specialist for life sciences, to Pharmaron, a fully integrated contract research organisation offering R&D services for the life science industry with over 4,000 employees, and operations in China, the United States, and the United Kingdom. Commercial details of the transaction are not being disclosed.

Xceleron, located in Germantown, Maryland, pioneered and developed the robust use of 14C microtracers and AMS analytical technology in pharmaceutical R&D. Since 1998, Xceleron has designed new preclinical and clinical investigations around the unique analytical features of AMS. With increased adoption, Xceleron developed a proprietary approach to ensure analytical robustness at very low levels of detection compared to complementary traditional platforms such as LC-MS/MS and Liquid Scintillation Counting. Benefiting from Xceleron’s work, AMS detection is now widely accepted as a valuable analytical tool in the quest for improved efficiency in pharmaceutical R&D.

Xceleron’s use of microtracers and AMS detection technology complements Pharmaron’s existing platforms of radiolabelled compound manufacturing and radiolabelled metabolism. The acquisition is part of Pharmaron’s strategy to provide fully integrated, end-to-end R&D services.